IDEXX Q3 Revenue Jumps 13.3% on Strong Product, Service Demand

TL;DR

**IDEXX is a buy; strong revenue and net income growth prove their market dominance, despite heavy share repurchases.**

AI Summary

IDEXX Laboratories, Inc. reported a strong financial performance for the three and nine months ended September 30, 2025. Total revenue for the three months increased by 13.3% to $1.105 billion from $975.5 million in the prior year, driven by product revenue growing 15.5% to $656.2 million and service revenue increasing 10.2% to $449.1 million. For the nine months, total revenue rose 9.2% to $3.213 billion from $2.943 billion. Net income for the three months jumped 17.9% to $274.6 million from $232.8 million, and for the nine months, it increased 20.8% to $811.3 million from $671.7 million. The company's gross profit for the three months was $683.4 million, up from $596.0 million, and for the nine months, it reached $2.001 billion, compared to $1.808 billion. Operating expenses saw an increase, with sales and marketing rising to $159.2 million for the three months and R&D increasing to $63.4 million. Cash and cash equivalents decreased by $80.1 million to $208.2 million from $288.3 million at the beginning of the period, primarily due to significant share repurchases totaling $979.2 million for the nine months.

Why It Matters

IDEXX's robust revenue and net income growth underscore the continued strength in the companion animal and livestock diagnostics market, signaling healthy demand for its products and services. This performance could attract more investors to the animal health sector, potentially driving up valuations for competitors like Zoetis and Heska. For employees, sustained growth often translates to job security and potential for expansion. Customers benefit from IDEXX's ongoing R&D investments, which reached $184.4 million for the nine months, promising innovative diagnostic solutions. The significant share repurchases, totaling $979.2 million, indicate management's confidence and commitment to returning value to shareholders, but also contributed to a decrease in cash reserves.

Risk Assessment

Risk Level: medium — The company's cash and cash equivalents decreased by $80.1 million to $208.2 million, largely due to substantial share repurchases of $979.2 million for the nine months ended September 30, 2025. This aggressive capital allocation strategy, while shareholder-friendly, reduces liquidity and could limit flexibility for future strategic investments or unexpected economic downturns. Additionally, long-term debt, net of current portion, decreased from $449.8 million to $374.8 million, but current portion of long-term debt remains at $149.9 million, indicating ongoing debt obligations.

Analyst Insight

Investors should consider IDEXX's strong operational performance and market position, but also monitor its cash management and debt levels. The significant share repurchases suggest management believes the stock is undervalued, which could be a positive signal for long-term holders. However, new investors should evaluate if the current valuation justifies the reduced liquidity from these repurchases.

Financial Highlights

debt To Equity

0.11

revenue

$1.105B

operating Margin

N/A

total Assets

$3.387B

total Debt

$829.8M

net Income

$274.6M

eps

$3.40

gross Margin

61.8%

cash Position

$208.2M

revenue Growth

+13.3%

Revenue Breakdown

Key Numbers

• $1.105B — Total Revenue (Q3 2025) (Increased 13.3% from $975.5 million in Q3 2024)
• $274.6M — Net Income (Q3 2025) (Increased 17.9% from $232.8 million in Q3 2024)
• $3.40 — Diluted EPS (Q3 2025) (Increased from $2.80 in Q3 2024)
• $3.213B — Total Revenue (YTD Sep 2025) (Increased 9.2% from $2.943 billion in YTD Sep 2024)
• $811.3M — Net Income (YTD Sep 2025) (Increased 20.8% from $671.7 million in YTD Sep 2024)
• $9.99 — Diluted EPS (YTD Sep 2025) (Increased from $8.05 in YTD Sep 2024)
• $979.2M — Repurchases of Common Stock (YTD Sep 2025) (Significant cash outflow for share buybacks)
• $208.2M — Cash and Cash Equivalents (Sep 30, 2025) (Decreased from $288.3 million at Dec 31, 2024)
• $184.4M — Research and Development Expenses (YTD Sep 2025) (Increased from $162.1 million in YTD Sep 2024)
• 79,851,330 — Common Stock Shares Outstanding (Oct 29, 2025) (Reflects impact of share repurchases)

Key Players & Entities

• IDEXX Laboratories, Inc. (company) — registrant
• NASDAQ Global Select Market (regulator) — exchange where common stock is registered
• U.S. Securities and Exchange Commission (regulator) — filing oversight
• U.S. Financial Accounting Standards Board (regulator) — accounting standards setter
• OPTI Medical Systems, Inc. (company) — wholly owned subsidiary of IDEXX
• Companion Animal Group (company) — reporting segment of IDEXX
• Livestock, Poultry and Dairy (company) — reporting segment of IDEXX
• Water (company) — reporting segment of IDEXX
• Roswell, Georgia (person) — location of OPTI Medical Systems, Inc.
• Westbrook Maine (person) — address of principal executive offices

FAQ

Risk Factors

• Supply Chain Disruptions [medium — operational]: The company relies on a global supply chain for its products. Any disruptions due to geopolitical events, natural disasters, or supplier issues could impact inventory levels and the ability to meet customer demand, potentially affecting revenue and profitability.
• Regulatory Compliance [medium — regulatory]: As a company operating in the animal health industry, IDEXX is subject to various regulations in different jurisdictions. Changes in these regulations, or failure to comply, could lead to product recalls, fines, or restrictions on market access, impacting financial performance.
• Competition [medium — market]: The animal health diagnostics market is competitive, with both large established players and smaller niche companies. Intense competition could lead to pricing pressures, reduced market share, and increased marketing expenses, affecting margins.
• Share Repurchase Impact on Cash [medium — financial]: Significant share repurchases totaling $979.2 million for the nine months have led to a decrease in cash and cash equivalents from $288.3 million to $208.2 million. While beneficial for EPS, a continued aggressive buyback strategy could strain liquidity if not balanced with strong cash flow generation.
• Integration of Acquisitions [low — operational]: While not explicitly detailed in this 10-Q, if IDEXX pursues growth through acquisitions, the successful integration of these businesses is critical. Failure to integrate effectively could result in unrealized synergies, operational inefficiencies, and financial underperformance.

Industry Context

IDEXX Laboratories operates in the global animal health diagnostics and software market. This sector is characterized by increasing pet ownership, rising demand for advanced veterinary care, and technological advancements in diagnostic tools. The industry is competitive, with a focus on innovation, product quality, and customer service to capture market share.

Regulatory Implications

The company must navigate a complex web of regulations related to animal health products, including those governing diagnostics, pharmaceuticals, and laboratory practices. Compliance with these evolving standards across different geographies is crucial to avoid penalties and maintain market access.

What Investors Should Do

1. Monitor share repurchase activity and its impact on cash reserves.
2. Analyze the growth drivers for product and service revenue.
3. Evaluate the increase in operating expenses, particularly Sales & Marketing and R&D.
4. Assess the company's debt levels and credit facility usage.

Key Dates

• 2025-09-30: End of Third Quarter 2025 — Reporting period for the financial results showing strong revenue and net income growth.
• 2025-10-29: Common Stock Shares Outstanding Date — Indicates 79,851,330 shares outstanding, reflecting the impact of share repurchases.
• 2025-12-31: End of Fiscal Year 2024 — Prior period balance sheet comparison point, showing $288.3 million in cash and cash equivalents.

Glossary

Gross Profit

The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. (Indicates the company's efficiency in production and service delivery, with a gross profit of $683.4 million for Q3 2025.)

Operating Expenses

Costs incurred by a business in its normal course of operations, excluding cost of goods sold. Includes sales and marketing, R&D, and general administrative expenses. (An increase in Sales and Marketing ($159.2M for Q3) and R&D ($63.4M for Q3) shows investment in growth and innovation.)

Treasury Stock

Stock that a company has repurchased from the open market. It is recorded at cost and appears as a contra-equity account. (The significant negative value of $6.3 billion in treasury stock reflects the company's substantial share repurchase program.)

Deferred Revenue

Revenue that has been received by a company for goods or services that have not yet been delivered or rendered. (Current portion of deferred revenue is $35.7 million, indicating future revenue obligations.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net identifiable assets. (Goodwill of $413.7 million suggests past acquisitions that are contributing to the company's value.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, IDEXX Laboratories has demonstrated robust growth. Total revenue for the three months ended September 30, 2025, increased by 13.3% to $1.105 billion, outpacing the 9.2% growth seen in the nine-month period. Net income also saw significant improvements, rising 17.9% for the quarter and 20.8% year-to-date. Gross margins have improved to 61.8% from approximately 61.1% in the prior year's quarter, indicating enhanced operational efficiency. However, cash and cash equivalents have decreased due to substantial share repurchases, a key financial activity to monitor.

Key Financial Figures

• $0.10 — ange on which registered Common Stock, $0.10 par value per share IDXX NASDAQ Global
• $1.25 billion — well-being of pets Credit Facility Our $1.25 billion five-year unsecured credit facility und
• $1 billion — ated credit agreement; consisting of i) $1 billion revolving credit facility, also referre
• $250 million — referred to as line of credit, and ii) $250 million three-year term loan FASB U.S. Financi

Filing Documents

• idxx-20250930.htm (10-Q) — 2232KB
• idxx2025q310-qexhibit311.htm (EX-31.1) — 10KB
• idxx2025q310-qexhibit312.htm (EX-31.2) — 10KB
• idxx2025q310-qexhibit321.htm (EX-32.1) — 6KB
• idxx2025q310-qexhibit322.htm (EX-32.2) — 6KB
• idxx-20250930_g1.gif (GRAPHIC) — 6KB
• 0000874716-25-000165.txt ( ) — 9938KB
• idxx-20250930.xsd (EX-101.SCH) — 58KB
• idxx-20250930_cal.xml (EX-101.CAL) — 87KB
• idxx-20250930_def.xml (EX-101.DEF) — 260KB
• idxx-20250930_lab.xml (EX-101.LAB) — 693KB
• idxx-20250930_pre.xml (EX-101.PRE) — 509KB
• idxx-20250930_htm.xml (XML) — 1688KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Income for the Three and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 8 Notes to Condensed Consolidated Financial Statements (Unaudited) 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 33 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 55 Item 4.

Controls and Procedures

Controls and Procedures 56

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 57 Item 1A.

Risk Factors

Risk Factors 57 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 57 Item 5. Other Information 57 Item 6. Exhibits 58

— FINANCIAL INFORMATION

PART I— FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements IDEXX LABORATORIES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except per share amounts) (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current Assets: Cash and cash equivalents $ 208,166 $ 288,266 Accounts receivable, net 566,881 473,575 Inventories 391,564 381,877 Other current assets 310,444 256,179 Total current assets 1,477,055 1,399,897 Long-Term Assets: Property and equipment, net 739,437 713,123 Operating lease right-of-use assets 128,207 116,129 Goodwill 413,651 405,100 Intangible assets, net 114,790 111,676 Other long-term assets 513,572 547,518 Total long-term assets 1,909,657 1,893,546 TOTAL ASSETS $ 3,386,712 $ 3,293,443 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 122,265 $ 114,211 Accrued liabilities 488,856 502,119 Credit facility 455,000 250,000 Current portion of long-term debt 149,997 167,787 Current portion of deferred revenue 35,693 33,799 Total current liabilities 1,251,811 1,067,916 Long-Term Liabilities: Deferred income tax liabilities 3,724 11,312 Long-term debt, net of current portion 374,825 449,786 Deferred revenue, net of current portion 31,051 26,939 Operating lease liabilities, net of current portion 106,494 97,836 Other long-term liabilities 57,621 44,341 Total long-term liabilities 573,715 630,214 Total liabilities 1,825,526 1,698,130 Commitments, Contingencies and Guarantees (Note 16) Stockholders' Equity: Common stock, $ 0.10 par value: Authorized: 120,000 shares; Issued: 108,301 shares in 2025 and 107,836 shares in 2024; Outstanding: 79,999 shares in 2025 and 81,604 shares in 2024 10,830 10,784 Additional paid-in capital 1,792,787 1,673,863 Deferred stock units: Outstanding: 60 units in 2025 and 60 units in 2024 6,229 5,885 Retained earnings 6,143,714 5,332,438 Accumulated other comprehensive loss ( 72,950 ) ( 93,645 ) Treasury stock, at cost: 28,303 shares in 2025 and 26,232 sha

View Full Filing

View this 10-Q filing on SEC EDGAR